The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
解锁市场时间线与信号动态
最近 90 天内有 4 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Medical Sales Representative
Medical Sales Representative
注册以查看完整信号动态
MENARINI Group 的国际扩张与竞争对手的对比情况
MENARINI Group你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 MENARINI Group你 | 2 | 0 | -67% | 4 | 12 |
Global Commercial Metrics Associate
查看职位Florence, Tuscany, Italy · 上周
Global Platforms Operations Associate - 12‑month fixed‑term contract
查看职位Florence, Tuscany, Italy · 2周前
Data Management Associate
查看职位Florence, Tuscany, Italy · 2周前
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
中国启动带状疱疹中西医结合诊疗专家共识全国巡讲,覆盖31个省份,为期一年,由美纳里尼支持,推动规范化诊疗落地。
Menarini集团和Stemline Therapeutics宣布在2026年ASCO年会上发表七项演讲,展示elacestrant和tagraxofusp在实体肿瘤和血液恶性肿瘤中的数据,包括转移性乳癌的联合疗法。
美纳里尼集团及Stemline Therapeutics将在2026年ASCO年会上展示elacestrant和tagraxofusp的新数据,涵盖实体肿瘤和血液恶性肿瘤共七项报告。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 MENARINI Group 的业务、市场和增长信号的快速解答。
